Effect of long-term mesoglycan treatment on fibrinogen plasma levels in patients with ischemic cerebrovascular disease

G. Orefice, E. Troisi, M. Selvaggio, V. Vecchione, S. Rubino, V. Provitera, P. B. Carrieri

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty patients who had previously had an atherothrombotic stroke received mesoglycan 50 mg BID for 3 months to evaluate the effect of the drug on plasma fibrinogen levels, antithrombin III concentration, and other coagulative parameters. After 7 days of treatment, mesoglycan significantly decreased plasma fibrinogen levels (P <0.05). This result was confirmed after 30 and 90 days (P <0.005 and P <0.001, respectively). No statistically significant changes in antithrombin III, prothrombin time, partial thromboplastin time, or platelet count were observed with respect to baseline values. No side effects were reported. Our results suggest that mesoglycan can effectively reduce plasma fibrinogen levels without interfering with other coagulative parameters.

Original languageEnglish
Pages (from-to)666-670
Number of pages5
JournalCurrent Therapeutic Research
Volume52
Issue number5
DOIs
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Effect of long-term mesoglycan treatment on fibrinogen plasma levels in patients with ischemic cerebrovascular disease'. Together they form a unique fingerprint.

Cite this